Cernák A, Kalafut F, Kusenda J, Novotná L
Bratisl Lek Listy. 1989 Jul;90(7):479-89.
Over the years 1977-1987 142 patients with malignant melanoma of the uvea were admitted to the Department of Ophthalmology, Teaching Hospital, Comenius University in Bratislava. Of the 119 patients treated by enucleation of the bulb 74.8% were alive after a mean follow up period of 5.9 years, whereas 25.2% of these patients died of consequences of metastases of the melanoma of the eye. The highest death rate was recorded in the first and second year following enucleation (57%) and then in the fourth year (17%). After the eighth year following enucleation of the bulb not a single case of death from consequences of metastases of melanoma was recorded. Eight patients with localization of the tumor in the anterior part of the uveal tract (iris, ciliary body) were treated by microsurgical removal of the tumor from the bulb. Two patients developed relapse of the tumor and the eyeballs had to be enucleated. After a mean follow up period of 6.6 years all these patients are alive and so far no signs of metastases have been observed. Moreover, the visual acuity has remained good in the patients whose eyes were not enucleated. Electrocoagulation was applied in six patients. Within a year the eyes had to be enucleated in three of them due to tumor progression. In two patients the growth of the tumor seems to have been stopped, yet regression of the tumor has not been observed. Complete healing was recorded only in one patient. After a mean follow up period of 4.5 years all the patients are alive without signs of metastases. A series of eight patients refused any kind of treatment of melanoma. Over a follow up period of 8.5 years six of them (75%) died of consequences of metastases within an average of 3.2 years from the establishment of diagnosis. Although the majority of these cases had small and middle sized melanomas, at present only two patients (25%) are still alive. In 127 patients with histologically proved malignant melanoma of the uvea the LAI test for the determination of uveal tumor antigen was also performed. The test was positive in 78.7% of the patients and negative in 23.3%. In a control group of patients with nontumorous eye diseases the LAI test was positive only in 2.9% and negative in 91.1%. Four months after enucleation of the bulb the LAI test was repeated and positivity was found to persist in 57.8% of the patients.(ABSTRACT TRUNCATED AT 400 WORDS)
1977年至1987年期间，142例葡萄膜恶性黑色素瘤患者住进了布拉迪斯拉发夸美纽斯大学教学医院眼科。在119例行眼球摘除术的患者中，平均随访5.9年后，74.8%的患者存活，而这些患者中有25.2%死于眼部黑色素瘤转移的后果。眼球摘除术后第一年和第二年的死亡率最高（57%），然后是第四年（17%）。眼球摘除术后第八年，未记录到因黑色素瘤转移后果而死亡的病例。8例肿瘤位于葡萄膜前部（虹膜、睫状体）的患者通过显微手术从眼球中切除肿瘤。2例患者肿瘤复发，不得不摘除眼球。平均随访6.6年后，所有这些患者均存活，迄今为止未观察到转移迹象。此外，未摘除眼球的患者视力保持良好。6例患者接受了电凝治疗。其中3例患者在一年内因肿瘤进展不得不摘除眼球。2例患者的肿瘤生长似乎已停止，但未观察到肿瘤消退。仅1例患者完全愈合。平均随访4.5年后，所有患者均存活，无转移迹象。一组8例患者拒绝接受任何黑色素瘤治疗。在8.5年的随访期内，其中6例（75%）在确诊后平均3.2年内死于转移后果。尽管这些病例大多数为中小型黑色素瘤，但目前仅有2例患者（25%）仍存活。对127例经组织学证实为葡萄膜恶性黑色素瘤的患者也进行了用于测定葡萄膜肿瘤抗原的LAI试验。该试验在78.7%的患者中呈阳性，在23.3%的患者中呈阴性。在一组非肿瘤性眼病患者的对照组中，LAI试验仅在2.9%的患者中呈阳性，在91.1%的患者中呈阴性。眼球摘除术后四个月重复进行LAI试验，发现57.8%的患者仍呈阳性。（摘要截取自400字）
